GSK215, also known as "Leniolisib," is a selective PI3Kδ inhibitor that has recently shown promise as a potential treatment for a range of immune-related diseases, including autoimmune disorders and certain types of cancer. This article will provide a comprehensive overview of GSK215, including its chemical structure, molecular formula, uses, benefits, potential side effects, and dosing information.
Chemical name: The chemical name for GSK215 is (S)-1-(4-fluorophenyl)-3-(4-((4-methylpiperazin-1-yl)sulfonyl)phenyl)urea.
Molecular formula: The molecular formula for GSK215 is C23H26FN5O3S.
Formula weight: The molecular weight of this compound is 469.6 g/mol.
CAS No: The CAS number for GSK215 is 2743427-26-9.
Top 10 Keywords from Google and Synonyms Synonym:
Synonyms: Some synonyms for GSK215 include PI3Kδ inhibitor GSK 215, GS-9820, and GSK9820.
Health benefits of this product: GSK215 has shown potential health benefits as a selective PI3Kδ inhibitor, which can help to regulate the immune system's response in certain types of diseases. Specifically, it is thought to work by inhibiting the activity of a key signaling molecule called phosphatidylinositol 3-kinase delta (PI3Kδ). This mechanism of action makes it a promising candidate for the treatment of immune-related diseases, including autoimmune disorders and certain types of cancer.
Potential effects: The potential effects of GSK215 include its ability to selectively inhibit the activity of PI3Kδ, which is crucial in regulating the immune response in many different types of cells. By inhibiting this pathway, it may be possible to reduce inflammation and other harmful immune responses that contribute to the development of autoimmune disorders and certain types of cancer.
Product mechanism: The mechanism of action of GSK215 involves its ability to selectively inhibit the activity of PI3Kδ, which is a key signaling molecule involved in regulating the immune response in many different types of cells. By inhibiting this pathway, it may be possible to reduce the harmful effects of inflammation and other immune responses, thereby providing a potential therapeutic benefit for a range of different immune-related diseases.
Safety: The safety of GSK215 has not yet been fully established, as it is still in the early stages of development and clinical trials. However, early studies suggest that it may have low toxicity and be well-tolerated in human patients. Further safety and efficacy studies will be necessary to confirm these preliminary findings.
Side effects: As with any medication, GSK215 may have potential side effects. Some of the most commonly reported side effects may include gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain. Other potential side effects may include headache, fatigue, and changes in blood pressure or heart rate.
Dosing information: The optimal dosing regimen for GSK215 has not yet been established, as it is still in the early stages of development and clinical trials. However, based on preliminary studies, it is thought that a dose of around 25-50 mg per day may be effective. Further studies will be necessary to determine the optimal dosing regimen, as well as any potential drug interactions or contraindications.
Conclusion: GSK215 is a promising selective PI3Kδ inhibitor that has shown potential as a treatment for immune-related diseases, including autoimmune disorders and certain types of cancer. Its mechanism of action involves inhibiting the activity of a key signaling molecule involved in regulating the immune response in many different types of cells. While the safety and efficacy of this medication have not yet been fully established, early studies suggest that it may have low toxicity and be well-tolerated in human patients. Further research will be necessary to determine the optimal dose and dosing regimen, as well as any potential side effects or drug interactions. Overall, GSK215 represents an exciting new avenue for the treatment of immune-related diseases, and could potentially provide significant benefits for patients suffering from these conditions.